Detalhe da pesquisa
1.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828933
2.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511784
3.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088119
4.
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Haematologica
; 106(9): 2354-2363, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054121
5.
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Eur J Haematol
; 105(1): 35-46, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32145111
6.
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
N Engl J Med
; 374(23): 2209-2221, 2016 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27276561
7.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 374(17): 1621-34, 2016 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27119237
8.
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Blood
; 130(24): 2610-2618, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29054911
9.
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Intern Med J
; 49(5): 598-606, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30411451
10.
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
J Clin Oncol
; 41(33): 5107-5117, 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506346
11.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
J Clin Oncol
; 41(5): 1035-1045, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36395435
12.
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
J Clin Oncol
; 39(22): 2430-2442, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34111952
13.
A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients.
J Antimicrob Chemother
; 62(4): 809-15, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18621987
14.
Precision oncology for acute myeloid leukemia using a knowledge bank approach.
Nat Genet
; 49(3): 332-340, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28092685
15.
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Lancet Haematol
; 4(5): e225-e236, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28336242
16.
Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemia.
Cancer Genet Cytogenet
; 165(1): 36-40, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16490595
17.
Not walking or communicating--is all well?
Lancet
; 372(9655): 2086, 2008 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-19070739
18.
Constitutional t(5;7)(q11;p15) rearranged to acquire monosomy 7q and trisomy 1q in a patient with myelodysplastic syndrome transforming to acute myelocytic leukemia.
Cancer Genet Cytogenet
; 149(2): 125-30, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15036888
19.
Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.
Leuk Lymphoma
; 45(1): 1-10, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15061191
20.
Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome.
Leuk Lymphoma
; 52(9): 1727-35, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21864043